Skip to main content

Advertisement

SpringerLink
Log in

Trabectedin: Novel Insights in the Treatment of Advanced Sarcoma

  • Evolving Therapies (R Bukowski, Section Editor)
  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Soft tissue sarcomas are a heterogenous group of malignancies with relatively high mortality rates. The outlook for these patients has been poor, with only a few drugs showing measurable activity. Trabectedin is a new alkylating agent with significant activity in sarcomas, but particularly in liposarcomas and leiomyosarcomas, both as a single agent or in combination with other drugs. Phase I and II studies of trabectedin have shown measurable benefit. Currently there are several Phase III trials which have completed accrual to better study its use as a single agent or in combination therapy, although outcomes have not yet been reported. Trabectedin (Yondelis) is approved for the treatment of sarcomas by the EMEA, but is not yet approved by the FDA, pending the results of the currently maturing phase III trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. García-Rocha M, García-Gravalos MD, Avila J. Characterisation of antimitotic products from marine organisms that disorganise the microtubule network: ecteinascidin-743, isohomohalichondrin-B and LL-15. Br J Cancer. 1996;73(8):875–83.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Pommier Y, Kohlhagen G, Bailly C, et al. dna sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the caribbean tunicate Ecteinascidia turbinata. Biochemistry. 1996;35(41):13303–9.

    Article  CAS  PubMed  Google Scholar 

  3. Fayette J, Coquarda IR, Albertia L, et al. ET-743: a novel agent with activity in soft tissue sarcomas. Oncologist. 2005;10(10):827–32.

    Article  CAS  PubMed  Google Scholar 

  4. Takebayashi Y, Goldwasser F, Urasaki Y, et al. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res. 2001;7:185–91.

    CAS  PubMed  Google Scholar 

  5. Martinez EJ, Corey EJ, Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin ET 743 and phthalascidin Pt 650. Chem Biol. 2001;8:1151–60.

    Article  CAS  PubMed  Google Scholar 

  6. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin-743 (ET-743) a natural marine compound with a unique mechanism of action. Eur J Cancer. 2001;37:97–105.

    Article  CAS  PubMed  Google Scholar 

  7. Giovanna D, Simonetta S, Laura C, et al. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001;92:583–8.

    Article  Google Scholar 

  8. Gajate C, An F, Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem. 2002;277(44):41580–9.

    Article  CAS  PubMed  Google Scholar 

  9. Izbicka E, Lawrence R, Raymond E, et al. In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol. 1998;9(9):981–7.

    Article  CAS  PubMed  Google Scholar 

  10. Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res. 2001;7:2908.

    CAS  PubMed  Google Scholar 

  11. Hendriks HR, Fiebig HH, Giavazzi R, et al. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol. 1999;10(10):1233–40.

    Article  CAS  PubMed  Google Scholar 

  12. American Cancer Society. Cancer facts and figures 2013. Atlanta: American Cancer Society; 2013.

    Google Scholar 

  13. SEER Cancer Statistics Review. 1975-2004. Table I-10 Age distribution at diagnosis and death

  14. National Cancer Institute, SEER Cancer Statistics Review. 1975-2004.

  15. Cancer Survival Among Adults: US SEER Program. 1988-2001. Patient and tumor characteristics, Sarcomas, Chapter 11, Table 11.6, page 4.

  16. Tanabe KK, Pollock RE, Ellis LM, et al. Influence of surgical margins on outcome in patients with preoperatively irradiated extremity soft tissue sarcomas. Cancer. 1994;73(6):1652.

    Article  CAS  PubMed  Google Scholar 

  17. McGee L, Indelicato DJ, Dagan R, et al. Long-term results following postoperative radiotherapy for soft tissue sarcomas of the extremity. Int J Radiat Oncol Biol Phys. 2012;84(4):1003–9.

    Article  PubMed  Google Scholar 

  18. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197.

    CAS  PubMed  Google Scholar 

  19. Rosenberg SA, Tepper J, Glatstein E, et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer. 1983;52(3):424–34.

    Article  CAS  PubMed  Google Scholar 

  20. Borden EC, Amato DA, Rosenbaum C, et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol. 1987;5:840–50.

    CAS  PubMed  Google Scholar 

  21. Schoenfeld DA, Rosenbaum C, Horton J, et al. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer. 1982;50:2757–62.

    Article  CAS  PubMed  Google Scholar 

  22. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537–45.

    CAS  PubMed  Google Scholar 

  23. Eriksson M. Histology-driven chemotherapy of soft-tissue sarcoma. Ann Oncol. 2010;21:vii270–6.

    Article  PubMed  Google Scholar 

  24. Edmonson JH, Marks RS, Buckner JC, et al. Contrast of response to dacarbazin, mitomycin, doxorubicin and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Inv. 2002;20:605–12.

    Article  CAS  Google Scholar 

  25. Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19:3483–9.

    CAS  PubMed  Google Scholar 

  26. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist. 2012;17:1213–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Leahy et al. Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The Sarcoma treatment and Burden of Illness in North America and Europe (SABINE) study. Ann Oncol. 2012. doi:10.1093/annonc/mds0.

    PubMed  Google Scholar 

  28. Gettys SC et al. New and emerging therapies for advanced or metastatic soft tissue sarcoma. J Oncol Pharm Pract. 2013;9:1078155213502370.

    Google Scholar 

  29. Delaloge S, Yovine A, Taamma A, et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients—preliminary evidence of activity. JCO. 2001;19(5):1248–55.

    CAS  Google Scholar 

  30. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of Ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22:1480–90.

    Article  CAS  PubMed  Google Scholar 

  31. Le Cesne A, Blay J-Y, Judson I, et al. Phase II Study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol. 2005;23:576–84.

    Article  PubMed  Google Scholar 

  32. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23:5484–92.

    Article  CAS  PubMed  Google Scholar 

  33. Roylance R, Seddon B, McTiernan A, et al. Experience of the use of trabectedin (ET-743, Yondelis™) in 21 patients with pre-treated advanced sarcoma from a single centre. Clin Oncol. 2007;19:572–6.

    Article  CAS  Google Scholar 

  34. Samuels BL, Chawla S, Patel S, von Mehren M, Hamm J, Kaiser PE, et al. Clinical outcomes and safety with trabectedin therapy in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access program study. Ann Oncol. 2013;24(6):1703–9.

    Google Scholar 

  35. Blay J-Y, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res. 2008;14:6656.

    Google Scholar 

  36. Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer. 2009;45(7):1153–61.

    Google Scholar 

  37. Fayette J, Boyle H, Chabaud S, Favier B, Engel C, Cassier P, Thiesse P, Méeus P, Sunyach MP, Vaz G, Ray-Coquard I, Ranchère D, Decouvelaere AV, Alberti L, Pérol D, Blay JY. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. Anticancer Drugs. 2010;21(1):113–9. doi:10.1097/CAD.0b013e328333057b.

    Google Scholar 

  38. Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012;48(4):579–85. doi:10.1016/j.ejca.2011.09.027.

    Google Scholar 

  39. Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2008;63:181–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  40. Vidal L, Magem M, Barlow C, et al. Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Inv New Drugs. 2012;30(2):616–28. doi:10.1007/s10637-010-9559-3.

    Article  CAS  Google Scholar 

  41. Chu Q, Mita A, Forouzesh B, et al. Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors. Clin Cancer Res. 2010;16(9):2656–65. doi:10.1158/1078-0432.CCR-10-0062.

    Article  CAS  PubMed  Google Scholar 

  42. Blay J-Y, Leahy MG, Nguyen BB, et al. Randomized multicenter phase III trial of trabectedin (T) versus doxorubicin-based chemotherapy as first-line therapy in patients with translocation-related sarcoma (TRS). 2012 ASCO Annual Meeting.

  43. Chawla SP, Leahy MG, Italiano A, et al. Results of a multivariate analysis for potential factors affecting outcome in translocation related sarcomas (TRS) treated with trabectedin or doxorubicin-based chemotherapy (DXCT) as first-line therapy ECCO 2013 P530 http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Searchable-Programme.aspx#anchorScpr

  44. Chawla SP, Italiano A, Patel S, et al. Safety of trabectedin versus doxorubicin-based chemotherapy (DXCT) as first-line therapy in patients with translocation-related sarcoma (TRS) ECCO 2013 P529 http://eccamsterdam2013.ecco-org.eu/Scientific-Programme/Searchable-Programme.aspx#anchorScpr

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Jay Patrick Lopez and Csaba Gajdos declare that they have no conflict of interest. Anthony Elias acts as an institutional PI for multiple sarcoma trials, including two with trabectedin.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Colorado at Denver, Denver, CO, USA

    Jay Patrick Lopez

  2. Department of Surgery, GITES Division, University of Colorado at Denver, Aurora, CO, USA

    Csaba Gajdos

  3. Department of Medicine, Medical Oncology Division, University of Colorado at Denver, AOP-3115, MS F-724 1635 Aurora Court, Aurora, CO, 80045, USA

    Anthony Elias

Authors
  1. Jay Patrick Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Csaba Gajdos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anthony Elias
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Elias.

Additional information

This article is part of the Topical Collection on Evolving Therapies

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lopez, J.P., Gajdos, C. & Elias, A. Trabectedin: Novel Insights in the Treatment of Advanced Sarcoma. Curr Oncol Rep 16, 387 (2014). https://doi.org/10.1007/s11912-014-0387-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11912-014-0387-z

Keywords

Search

Navigation